MX343688B - Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. - Google Patents
Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.Info
- Publication number
- MX343688B MX343688B MX2013012923A MX2013012923A MX343688B MX 343688 B MX343688 B MX 343688B MX 2013012923 A MX2013012923 A MX 2013012923A MX 2013012923 A MX2013012923 A MX 2013012923A MX 343688 B MX343688 B MX 343688B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- making
- same
- sulfonamide compounds
- compounds
- Prior art date
Links
- LSJVQKDTVCDSPE-UHFFFAOYSA-N 1h-pyrazole-5-sulfonamide Chemical class NS(=O)(=O)C=1C=CNN=1 LSJVQKDTVCDSPE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 abstract 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- -1 sulfonamide compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483275P | 2011-05-06 | 2011-05-06 | |
| PCT/US2012/036793 WO2012154679A1 (en) | 2011-05-06 | 2012-05-07 | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012923A MX2013012923A (es) | 2014-02-27 |
| MX343688B true MX343688B (es) | 2016-11-16 |
Family
ID=46085253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012923A MX343688B (es) | 2011-05-06 | 2012-05-07 | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9242997B2 (enExample) |
| EP (1) | EP2705035B1 (enExample) |
| JP (1) | JP6035327B2 (enExample) |
| KR (1) | KR20140040739A (enExample) |
| CN (1) | CN103764652B (enExample) |
| AU (1) | AU2012253760B2 (enExample) |
| BR (1) | BR112013028666A2 (enExample) |
| CA (1) | CA2835209A1 (enExample) |
| MX (1) | MX343688B (enExample) |
| WO (1) | WO2012154679A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
| CA2786603C (en) | 2010-01-08 | 2018-02-20 | James E. Vath | Fumagillol type compounds and methods of making and using same |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン，インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
| CA2819251A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン，インコーポレイテッド | オキサスピロ［２．５］オクタン誘導体および類似体 |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| KR101979039B1 (ko) * | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| EP2804856B1 (en) | 2012-01-18 | 2017-03-15 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112014028041A2 (pt) | 2012-05-08 | 2017-06-27 | Zafgen Inc | tratamento de obesidade hipotalâmica com inibidores de metap2 |
| CA2873574A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumagillol type compounds and methods of making and using same |
| CN104918615B (zh) | 2012-11-05 | 2018-10-12 | 扎夫根股份有限公司 | 治疗肝病的方法 |
| BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| AU2014236528A1 (en) | 2013-03-14 | 2015-09-24 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
| CN104592122B (zh) * | 2014-12-09 | 2018-01-23 | 凯莱英医药集团（天津）股份有限公司 | 3‑(4‑甲基‑1h‑咪唑‑1‑基)‑5‑(三氟甲基)苯胺的制备方法 |
| HUE049144T2 (hu) * | 2015-04-09 | 2020-08-28 | Orion Corp | Eljárás anrdogén receptorantagonisták és azok intermedierjeinek elõállítására |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| WO2025149636A1 (en) | 2024-01-10 | 2025-07-17 | Baumann Samira | Ultrasound transducer and method for generating ultrasound signals for digital communication via ultrasound trasmission |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| EP0359036B1 (en) | 1988-09-01 | 1997-03-26 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives |
| US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
| EP0387650B1 (en) | 1989-03-06 | 1993-03-31 | Takeda Chemical Industries, Ltd. | 6-epifumagillols, production and use thereof |
| US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (enExample) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| JPH05107705A (ja) * | 1991-10-17 | 1993-04-30 | Konica Corp | 新規な写真用カプラー |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
| EP0602586B1 (en) | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| AP646A (en) | 1995-03-27 | 1998-04-27 | Sanofi Synthelabo | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. |
| CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| WO1998005293A2 (en) | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
| DE69819878T2 (de) | 1997-03-04 | 2004-04-22 | Monsanto Co. | Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| EP1024801B1 (en) | 1997-10-31 | 2004-06-23 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| CA2300197A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| IL145923A0 (en) | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| EP1223932A4 (en) | 1999-10-01 | 2003-01-15 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| AR030631A1 (es) | 2000-09-29 | 2003-08-27 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7084108B2 (en) | 2000-11-01 | 2006-08-01 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| AU2002246726B2 (en) | 2000-12-20 | 2007-03-01 | Bristol-Myers Squibb Company | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| WO2002078699A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Compounds and methods |
| US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| CA2534887A1 (en) | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| TW200530157A (en) | 2003-09-09 | 2005-09-16 | Japan Tobacco Inc | Dipeptidyl peptidase iv inhibitor |
| WO2005063767A2 (en) | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| CA2550873A1 (en) | 2003-12-29 | 2005-07-21 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| WO2006004803A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| WO2006036670A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| EP1841761A4 (en) | 2005-01-26 | 2008-10-29 | Chong Kun Dang Pharm Corp | Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| KR20080083680A (ko) | 2005-12-23 | 2008-09-18 | 스미스클라인 비참 코포레이션 | 오로라 키나제의 아자인돌 억제제 |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
| EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| EA020251B1 (ru) | 2007-11-28 | 2014-09-30 | Мерсана Терапьютикс, Инк. | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина |
| CN101932577B (zh) | 2007-11-30 | 2013-07-17 | 拜耳知识产权有限责任公司 | 杂芳基取代的哌啶 |
| CA2731020A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| EP2350012B1 (en) | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| WO2010048499A1 (en) | 2008-10-24 | 2010-04-29 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
| US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| WO2011150338A1 (en) | 2010-05-27 | 2011-12-01 | Zafgen Corporation | Methods of treating obesity |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン，インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| US20140073691A1 (en) | 2010-11-10 | 2014-03-13 | Zafgen, Inc. | Methods and composition for Treating Thyroid Hormone Related Disorders |
| CA2819251A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| KR101979039B1 (ko) | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
| EP2804856B1 (en) | 2012-01-18 | 2017-03-15 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
-
2012
- 2012-05-07 BR BR112013028666A patent/BR112013028666A2/pt active Search and Examination
- 2012-05-07 US US14/116,029 patent/US9242997B2/en not_active Expired - Fee Related
- 2012-05-07 KR KR1020137032333A patent/KR20140040739A/ko not_active Withdrawn
- 2012-05-07 EP EP12721140.7A patent/EP2705035B1/en active Active
- 2012-05-07 WO PCT/US2012/036793 patent/WO2012154679A1/en not_active Ceased
- 2012-05-07 CA CA2835209A patent/CA2835209A1/en not_active Abandoned
- 2012-05-07 JP JP2014509512A patent/JP6035327B2/ja not_active Expired - Fee Related
- 2012-05-07 AU AU2012253760A patent/AU2012253760B2/en not_active Ceased
- 2012-05-07 MX MX2013012923A patent/MX343688B/es active IP Right Grant
- 2012-05-07 CN CN201280033357.9A patent/CN103764652B/zh not_active Expired - Fee Related
-
2015
- 2015-12-14 US US14/968,013 patent/US20160324865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014513140A (ja) | 2014-05-29 |
| US20160324865A1 (en) | 2016-11-10 |
| AU2012253760A1 (en) | 2013-11-21 |
| US20140080822A1 (en) | 2014-03-20 |
| WO2012154679A8 (en) | 2013-11-14 |
| EP2705035A1 (en) | 2014-03-12 |
| AU2012253760B2 (en) | 2016-02-04 |
| JP6035327B2 (ja) | 2016-11-30 |
| BR112013028666A2 (pt) | 2017-08-08 |
| US9242997B2 (en) | 2016-01-26 |
| CA2835209A1 (en) | 2012-11-15 |
| EP2705035B1 (en) | 2016-12-14 |
| KR20140040739A (ko) | 2014-04-03 |
| WO2012154679A1 (en) | 2012-11-15 |
| MX2013012923A (es) | 2014-02-27 |
| CN103764652B (zh) | 2016-03-23 |
| CN103764652A (zh) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| PH12013502261A1 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| GB201118656D0 (en) | New compounds | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| TN2012000533A1 (en) | New forms of rifaximin and uses thereof | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MX2015014083A (es) | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |